Vice President, Head of Strategy & Portfolio Analysis, IQVIA
With the broader availability of data, both on drugs and patients, as well as better sources of data in emerging markets, through both public and proprietary sources, life science companies are applying it in both portfolio and product investment decisions. What data are companies using and what new insights do they find most valuable? What […]